Synthesis and SAR of α-acylaminoketone ligands for control of gene expression

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 3, 2003, Pages 475-478

  Tice, Colin M ^a   Hormann, Robert E ^a   Thompson, Christine S ^a   Friz, Jennifer L ^a   Cavanaugh, Caitlin K ^a   Michelotti, Enrique L ^b,d   Garcia, Javier ^b,c   Nicolas, Ernesto ^c   Albericio, Fernando ^c  

^a RHeoGene   (United States)

^b ROHM AND HAAS COMPANY   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Locus Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECDYSONE; HYDRAZINE DERIVATIVE; KETONE DERIVATIVE; RH 5849;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG POTENCY; DRUG SYNTHESIS; GENE EXPRESSION; MAMMAL CELL; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; REPORTER GENE; SILKWORM; STRUCTURE ACTIVITY RELATION;

AMINES; ANIMALS; BETA-GALACTOSIDASE; BOMBYX; CELLS, CULTURED; ECDYSONE; GENE EXPRESSION; INDICATORS AND REAGENTS; KETONES; LETHAL DOSE 50; MICE; MOLECULAR CONFORMATION; RECEPTORS, STEROID; STRUCTURE-ACTIVITY RELATIONSHIP;

BOMBYX; BOMBYX MORI; MAMMALIA;

EID: 0037330768     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00980-0     Document Type: Article

References (24)

1. DeMayo F.J., Tsai S.Y. Trends in Endocrinology & Metabolism. 12:2001;348.
2. Clackson T. Gene Therapy. 7:2000;120.
3. Zuo J., Chua N.-H. Curr. Opin. Biotechnology. 11:2000;146.
4. Christopherson K.S., Mark M.R., Bajaj V., Godowski P.J. Proc. Natl. Acad. Sci. U.S.A. 89:1992;6314.
5. Suhr S.T., Gil E.B., Senut M.-C., Gage F.H. Proc. Natl. Acad. Sci. U.S.A. 95:1998;7999.
6. Martinez A., Sparks C., Hart C.A., Thompson J., Jepson I. The Plant Journal. 19:1999;97.
7. Hoppe U.C., Marban E., Johns D.C. Molecular Therapy. 1:2000;159.
8. Kumar, M. B.; Fujimoto, T.; Potter, D. W.; Deng, Q.; Palli, S. R. Proc. Natl. Acad. Sci. U.S.A., in press.
9. Wing K.D., Slawecki R.A., Carlson G.R. Science. 241:1988;470.
10. Carlson, G. R.; Cress, D. E.; Dhadialla, T. S.; Hormann, R. E.; Le, D. P. U.S. Patent 6,258,603, 2001; Chem. Abstr. 2001, 135, 72148.
11. For other orthogonal systems see: (a) Moradpour D., Englert C., Blum H.E. Biol. Chem. 379:1998;1189 (b) Shi Y., Koh J.T. Chemistry & Biology. 8:2001;501 (c) Tedesco R., Thomas J.A., Katzenellenbogen B.S., Katzenellenbogen J.A. Chemistry & Biology. 8:2001;277 (d) Doyle D.F., Braasch D.A., Jackson L.K., Weiss H.E., Boehm M.F., Mangelsdorf D.J., Corey D.R. J. Am. Chem. Soc. 123:2001;11367.
12. For other orthogonal systems see: (a) Moradpour D., Englert C., Blum H.E. Biol. Chem. 379:1998;1189 (b) Shi Y., Koh J.T. Chemistry & Biology. 8:2001;501 (c) Tedesco R., Thomas J.A., Katzenellenbogen B.S., Katzenellenbogen J.A. Chemistry & Biology. 8:2001;277 (d) Doyle D.F., Braasch D.A., Jackson L.K., Weiss H.E., Boehm M.F., Mangelsdorf D.J., Corey D.R. J. Am. Chem. Soc. 123:2001;11367.
13. For other orthogonal systems see: (a) Moradpour D., Englert C., Blum H.E. Biol. Chem. 379:1998;1189 (b) Shi Y., Koh J.T. Chemistry & Biology. 8:2001;501 (c) Tedesco R., Thomas J.A., Katzenellenbogen B.S., Katzenellenbogen J.A. Chemistry & Biology. 8:2001;277 (d) Doyle D.F., Braasch D.A., Jackson L.K., Weiss H.E., Boehm M.F., Mangelsdorf D.J., Corey D.R. J. Am. Chem. Soc. 123:2001;11367.
14. For other orthogonal systems see: (a) Moradpour D., Englert C., Blum H.E. Biol. Chem. 379:1998;1189 (b) Shi Y., Koh J.T. Chemistry & Biology. 8:2001;501 (c) Tedesco R., Thomas J.A., Katzenellenbogen B.S., Katzenellenbogen J.A. Chemistry & Biology. 8:2001;277 (d) Doyle D.F., Braasch D.A., Jackson L.K., Weiss H.E., Boehm M.F., Mangelsdorf D.J., Corey D.R. J. Am. Chem. Soc. 123:2001;11367.
15. Garcia J., Nicolas E., Albericio F., Michelotti E.L., Tice C.M. Tetrahedron Lett. 43:2002;7495.
16. Compound 2aa has been reported previously: Hassner A., Burke S.S., Jesse C.I. J. Am. Chem. Soc. 97:1975;4692.
17. Farnum D.G., Carlson G.R. Synthesis. 1972;191.
18. 2 for 24 h. Ligand stock solutions were prepared (10 mM in DMSO) and diluted 100-fold in media. 50 μL of diluted ligand solution was added to each well. The final concentration of DMSO was maintained at 0.03% in both controls and treatments. β-Galactosidase reporter gene expression was measured 48 h after treatment of the cells using Gal Screen™ bioluminescent reporter gene assay system from Tropix (GSY1000). Luminescence was detected at room temperature using a Dynex MLX microtiter plate luminometer. Fold inductions were calculated by dividing relative light units (RLU) in ligand treated cells with RLU in DMSO treated cells.
19. Kemp A., Ner S.K., Rees L., Suckling C.J., Tedford M.C., Bell A.R., Wrigglesworth R. J. Chem. Soc., Perkin Trans. 2. 1993;741.
20. Graham S.L., Scholz T.H. Tetrahedron Lett. 31:1990;6269.
21. Ruble J.C., Fu G.C. J. Am. Chem. Soc. 120:1998;11532.
22. 3) δ 12.1, 17.1, 17.4, 17.5, 21.5, 34.3, 55.6, 67.5, 111.3, 118.3, 125.0, 125.1, 126.5, 127.7, 129.2, 132.5, 136.7, 137.6, 137.9, 158.0, 168.9, 201.0. The 3rd fraction (50% ether in hexanes) contained additional 2di (34.5 mg, 20%) of lower purity.
23. Breitenbucher J.G., Arienti K.L., McClure K.J. J. Comb. Chem. 3:2001;528.
24. -1. MS (ESI, +ve ion) m/z 366 (M+1).